Neoadjuvant and adjuvant systemic therapy for newly diagnosed stage II- IV epithelial ovary, fallopian tube, or primary peritoneal carcinoma: A systematic review-Reference-Cited by-同舟云学术

Neoadjuvant and adjuvant systemic therapy for newly diagnosed stage II- IV epithelial ovary, fallopian tube, or primary peritoneal carcinoma: A systematic review

Published:2021-06 Issue: Volume:162 Page:103324
ISSN:1040-8428
Container-title:Critical Reviews in Oncology/Hematology
language:en
Short-container-title:Critical Reviews in Oncology/Hematology

Author:

Hirte Hal,Poon Raymond^ORCID,Yao Xiaomei,May Taymaa,Ethier Josee-Lyne^ORCID,Petz Lauri,Speakman Jane,Elit Laurie^ORCID

Publisher

Elsevier BV

Subject

Oncology,Hematology

Reference65 articles.

1. Randomized phase 3 trial of interferon gamma-1b plus standard carboplatin/paclitaxel versus carboplatin/paclitaxel alone for first-line treatment of advanced ovarian and primary peritoneal carcinomas: Results from a prospectively designed analysis of progression-free survival

2. Predictive blood-based biomarkers in patients with epithelial ovarian cancer treated with carboplatin and paclitaxel with or without Bevacizumab: results from GOG-0218;Alvarez Secord;Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res.,2020

3. Paclitaxel plus carboplatin versus paclitaxel plus alternating carboplatin and cisplatin for initial treatment of advanced ovarian cancer: long-term efficacy results: a Hellenic Cooperative Oncology Group (HeCOG) study;Aravantinos;Ann. Oncol.,2005

4. Carboplatin and paclitaxel versus cisplatin, paclitaxel and doxorubicin for first-line chemotherapy of advanced ovarian cancer: a hellenic cooperative oncology group (HeCOG) study;Aravantinos;Eur. J. Cancer,2008

5. Intraperitoneal cisplatin and paclitaxel in ovarian cancer;Armstrong;N. Engl. J. Med.,2006

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Optimizing Outcomes: Bevacizumab with Carboplatin and Paclitaxel in 5110 Ovarian Cancer Patients—A Systematic Review and Meta-Analysis;Pharmaceuticals;2024-08-21

2. Consenso de expertos basado en la evidencia: perfilamiento y manejo del carcinoma epitelial de ovario de alto grado avanzado;Revista Colombiana de Obstetricia y Ginecología;2024-06-14

3. Is a low dose of dexamethasone sufficient to prevent paclitaxel-related hypersensitivity reactions? A retrospective study in patients with gynecologic malignancy;Expert Review of Clinical Pharmacology;2024-04-23

4. Neoadjuvant chemotherapy in advanced epithelial ovarian cancer by histology: A SEER based survival analysis;Medicine;2023-01-27

5. A novel form of docetaxel polymeric micelles demonstrates anti-tumor and ascites-inhibitory activities in animal models as monotherapy or in combination with anti-angiogenic agents;Frontiers in Pharmacology;2022-08-24